10-Q: Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sentiment:

Quarterly Report 23 October 2024 5:00 PM

📋All filings for Viking Therapeutics, INC

Viking Therapeutics' third quarter 2024 report details increased R&D spending, a net loss, and a strong cash position to fund operations through at least 2025.

Capital raiseThe company completed an underwritten public offering of its common stock in March 2024, raising net proceeds of $597.1 million.The company may sell shares of its common stock for remaining gross proceeds of up to $151.9 million from time to time pursuant to the ATM Prospectus.

Worse than expectedThe company reported a net loss of $24.9 million for the quarter and $74.5 million for the nine months ended September 30, 2024, which is worse than the prior year periods.Research and development expenses increased significantly to $22.8 million for the quarter and $70.7 million for the nine months ended September 30, 2024, which is worse than the prior year periods.General and administrative expenses also increased to $13.8 million for the quarter and $34.0 million for the nine months ended September 30, 2024, which is worse than the prior year periods.

Summary

Viking Therapeutics, a clinical-stage biopharmaceutical company, released its financial results for the third quarter ended September 30, 2024.
The company reported a net loss of $24.9 million for the quarter and $74.5 million for the nine months ended September 30, 2024.
Research and development expenses increased to $22.8 million for the quarter and $70.7 million for the nine months ended September 30, 2024, primarily due to increased manufacturing, clinical study, and stock-based compensation costs.
General and administrative expenses also increased to $13.8 million for the quarter and $34.0 million for the nine months ended September 30, 2024, driven by higher stock-based compensation, legal, and consulting fees.
The company's cash, cash equivalents, and short-term investments totaled $930.4 million as of September 30, 2024.
Viking believes its current cash position is sufficient to fund operations through at least December 31, 2025.
The company has been focused on the development of novel therapies for metabolic and endocrine disorders, including VK2735, VK2809, and VK0214.
Viking completed a public offering in March 2024, raising net proceeds of $597.1 million.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is advancing its clinical programs, it also reported a significant net loss and increased expenses. The company's future success depends on the outcome of its clinical trials and regulatory approvals.

Positives

Viking Therapeutics has a strong cash position of $930.4 million, which is expected to fund operations through at least December 31, 2025.
The company successfully completed a public offering in March 2024, raising $597.1 million in net proceeds.
Viking is actively advancing its clinical programs for VK2735, VK2809, and VK0214.
The company has a diversified pipeline of drug candidates targeting metabolic and endocrine disorders.

Negatives

Viking Therapeutics reported a net loss of $24.9 million for the third quarter of 2024 and $74.5 million for the nine months ended September 30, 2024.
Research and development expenses increased significantly to $22.8 million for the quarter and $70.7 million for the nine months ended September 30, 2024.
General and administrative expenses also increased to $13.8 million for the quarter and $34.0 million for the nine months ended September 30, 2024.

Risks

The company is a clinical-stage company with a limited operating history and is expected to incur significant operating losses.
Viking is substantially dependent on technologies licensed from Ligand Pharmaceuticals.
The company is dependent on the success of its current drug candidates, and there is no guarantee of regulatory approval or commercialization.
Delays in clinical trials could increase costs and delay strategic collaborations.
Viking relies on third parties to conduct preclinical studies and clinical trials, which poses risks if these parties fail to meet their obligations.
The company faces intense competition from other biopharmaceutical companies.
Unstable market and economic conditions may have adverse consequences on the business.
There is a risk of not obtaining or maintaining necessary rights to drug candidates through acquisitions and in-licenses.
Failure to comply with obligations in agreements with licensors could result in the loss of intellectual property rights.
The company may not be successful in obtaining or maintaining orphan drug designation or exclusivity for its product candidates.
Manufacturing risks could increase costs and limit the supply of drug candidates.
The company may not be able to obtain adequate reimbursement for its products from third-party payors.
Compliance with global privacy and data security requirements could result in additional costs and liabilities.
The company is subject to anti-corruption, anti-money laundering, export control, and other trade laws and regulations.
The company may be unable to retain current members of senior management and scientific personnel or attract and keep additional key personnel.
The company is exposed to product liability, non-clinical, and clinical liability risks.
The company's research and development activities involve the use of hazardous materials.
The company relies significantly on information technology, and any failure or security lapse could harm its ability to operate effectively.
The company is at risk of employee or consultant misconduct.
Business disruptions such as natural disasters could seriously harm the company's future revenues and financial condition.
The company may engage in strategic transactions that could impact its liquidity, increase expenses, and present significant distractions to management.
The company's employment agreements with officers and certain employees may require severance benefits in the event of a change in control.
Investors' expectations of the company's performance relating to environmental, social, and governance factors may impose additional costs and expose the company to new risks.
The impact of the Russian invasion of Ukraine and the Israel-Hamas war on the global economy, energy supplies, and raw materials is uncertain but may negatively impact the company's business and operations.
The market price of the company's common stock may be highly volatile.
The company's management owns a significant percentage of the stock and will be able to exert significant control over matters subject to stockholder approval.
The company is no longer a smaller reporting company and is subject to certain enhanced disclosure requirements.
The company's internal control over financial reporting may not meet the standards required by Section 404 of the Sarbanes-Oxley Act.
The company is at risk of securities class action litigation.
The company's ability to use its net operating loss carryforwards may be subject to certain limitations.
The company may never pay dividends on its common stock.
Provisions in the company's charter documents and Delaware law could make it more difficult or expensive for a third party to acquire the company.
The company's bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by its stockholders.

Future Outlook

Viking plans to advance the subcutaneous formulation of VK2735 into Phase 3 development and initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later in 2024. The company believes its current cash position is sufficient to fund operations through at least December 31, 2025.

Management Comments

Management believes that the company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Management believes that the company has sufficient capital to fund its operating and capital requirements for at least the next 12 months.

Industry Context

Viking Therapeutics is operating in the competitive biopharmaceutical industry, focusing on metabolic and endocrine disorders. The company faces competition from established pharmaceutical companies and other emerging biotechs developing therapies for obesity, MASH/NASH, and other related conditions. The company's success will depend on its ability to demonstrate the safety and efficacy of its drug candidates and secure regulatory approvals.

Comparison to Industry Standards

Viking's increased R&D spending is consistent with other clinical-stage biopharmaceutical companies focused on advancing their drug pipelines.
The company's net loss is typical for a company at this stage of development, as it is investing heavily in clinical trials and research.
Viking's strong cash position is a positive sign, as it provides the company with the financial flexibility to continue its development programs.
The company's focus on metabolic and endocrine disorders aligns with the growing market demand for treatments in these areas.
The company's clinical trial results for VK2735 and VK2809 are promising and could position it as a competitor in the obesity and MASH/NASH markets.
Compared to companies like Novo Nordisk and Eli Lilly, which have approved drugs for obesity, Viking is still in the clinical development phase but has shown promising results.
Compared to Madrigal Pharmaceuticals, which has an approved drug for MASH/NASH, Viking is also in the clinical development phase but has shown positive 52-week histologic data.
Viking's approach to X-ALD with VK0214 is unique, as there are limited approved treatments for this rare disease, and the company's Phase 1b results are encouraging.

Legal Proceedings

In December 2022, Viking filed suit against Ascletis Bioscience Co., Ltd., Gannex Pharma Co., Ltd., Ascletis Pharmaceuticals Co., Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu, alleging trade secret misappropriation and other claims.
In a related action, Viking also filed suit against the same Ascletis Defendants in the International Trade Commission for unlawful and unfair methods of competition.
On October 3, 2024, the ITCs Chief Administrative Law Judge issued a Notice of his determination in favor of Viking, stating that Ascletis Defendants misappropriated trade secrets and engaged in discovery misconduct.

Stakeholder Impact

Shareholders: The company's financial performance and clinical trial results will directly impact shareholder value.
Employees: The company's growth and success will affect employee job security and opportunities.
Customers: The company's drug candidates, if approved, will provide new treatment options for patients with metabolic and endocrine disorders.
Suppliers: The company's manufacturing and supply chain partners will be impacted by the company's development and commercialization activities.
Creditors: The company's financial stability and ability to repay debts will be of interest to creditors.

Next Steps

Viking plans to advance the subcutaneous formulation of VK2735 into Phase 3 development.
The company plans to initiate a Phase 2 trial with the oral formulation of VK2735 in obesity later in 2024.

Key Dates

Date	Description
2012-09-24	Viking Therapeutics, Inc. was incorporated.
2014-02-20	Grant date for stock purchase agreement with one of the founders.
2014-05-21	Viking entered into the Master License Agreement with Ligand Pharmaceuticals Incorporated.
2015-05-01	Viking repurchased 633,810 shares of common stock.
2016-10-01	A triggering event became probable of occurrence and was deemed achieved in October 2016 and 183,095 shares vested.
2016-12-01	Viking received orphan drug designation from the FDA for VK0214.
2017-11-01	Viking announced positive top-line results from a Phase 2 clinical trial for VK5211.
2018-01-01	Viking adopted Financial Accounting Standards Board (FASB) Accounting Standards Update No. 2014-09.
2019-11-01	Viking initiated the VOYAGE study, a Phase 2b clinical trial of VK2809.
2020-01-01	Viking issued 244,000 PRSU awards to several of its employees.
2021-01-01	Viking issued 205,500 PRSU awards to several of its employees.
2021-06-01	Viking initiated a Phase 1b clinical trial of VK0214 in patients with X-ALD.
2021-07-28	Viking entered into an At-The-Market Equity Offering Sales Agreement.
2021-11-15	Viking entered into the Office Lease.
2022-01-01	Viking issued 657,000 PRSU awards to several of its employees.
2022-01-01	Viking announced the initiation of a Phase 1 clinical trial of VK2735.
2022-03-10	Viking's Board of Directors authorized a stock repurchase program.
2022-03-18	Stock repurchase program became effective.
2022-12-01	Viking filed suit against Ascletis Defendants.
2023-01-01	Viking issued 920,000 PRSU awards to several of its employees.
2023-01-01	Viking announced completion of patient enrollment in the VOYAGE study.
2023-03-28	Viking announced the completion of the Phase 1 trial of VK2735 and the initiation of a Phase 1 clinical study to evaluate a novel oral formulation of VK2735.
2023-04-03	Viking completed an underwritten public offering of its common stock.
2023-05-01	Viking reported positive top-line results from the VOYAGE study.
2023-07-26	Viking filed an automatic universal shelf registration statement on Form S-3 and entered into an Amendment No. 1 to At-The-Market Equity Offering Sales Agreement.
2023-09-01	Viking initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity.
2023-10-01	Viking announced completion of patient enrollment in the Phase 2 VENTURE study.
2024-01-01	Viking issued 677,500 PRSU awards to several of its employees.
2024-01-01	Viking ceased to be a smaller reporting company.
2024-01-04	Cancellation date of 77,834 PRSU awards.
2024-02-27	Viking announced positive results from the Phase 2 VENTURE study.
2024-03-04	Viking completed an underwritten public offering of its common stock.
2024-03-26	Viking announced positive results from the 28-day MAD study of oral VK2735.
2024-05-20	166,816 shares of the Company's common stock were purchased by participants of the 2014 ESPP.
2024-05-21	Viking's stockholders approved the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan.
2024-06-01	Viking announced positive 52-week histologic data from the VOYAGE study.
2024-07-29	Greg Zante adopted a Rule 10b5-1 trading arrangement.
2024-09-30	End of the reporting period for the third quarter 2024.
2024-10-03	The ITCs Chief Administrative Law Judge issued a Notice of his determination in favor of Viking.
2024-10-15	Number of shares outstanding as of this date: 111,436,384.
2024-10-23	Date of filing of this Quarterly Report on Form 10-Q.
2024-10-01	Viking announced results from the Phase 1b clinical trial of VK0214.

Keywords

Viking Therapeutics, Biopharmaceutical, Clinical-stage, Metabolic disorders, Endocrine disorders, VK2735, VK2809, VK0214, Research and development, Clinical trials, Financial results, Net loss, Cash position, Stock offering, Obesity, MASH/NASH, X-ALD

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.